Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib, Tucatinib, and Trastuzumab +/- Fulvestrant in HER2+ Breast Cancer
NCT05319873Phase 2Active, not recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Apr 2022
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ribociclib, tucatinib in breast cancer, sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Apr 2022; status: active, not recruiting.
02
Drugs
ribociclibtucatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05319873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05319873.